Hanz Biotech has established a dual-track strategy centered on nucleic acid drug delivery and the translation of innovative therapies—comprising both a technical service platform and a portfolio of standardized products. This structure is designed to meet the diverse needs of research institutions and biopharmaceutical companies across various stages, from basic research and technical validation to cutting-edge therapeutic development. Our services and products are focused on addressing key industry challenges such as low delivery efficiency, difficulties in extrahepatic targeting, and high technical barriers. Hanz is committed to becoming a next-generation leader in RNA delivery technologies and their translational applications.